每周一次CagriSema治疗2型糖尿病的3a期研究
REIMAGINE 1是一项随机双盲安慰剂对照3a期研究,纳入189例饮食运动控制不佳的2型糖尿病患者,评估每周一次cagrilintide-semaglutide的疗效与安全性。40周时,两个剂量组HbA1c降幅和体重降幅均显著优于安慰剂,安全性与GLP-1受体激动剂类一致。
要点
- 不良事件多为轻中度,以胃肠道相关为主。
核心结论
- 在饮食运动控制不佳的早期2型糖尿病患者中,cagrilintide-semaglutide两个剂量组的HbA1c降幅均优于安慰剂。
- 安全性与GLP-1受体激动剂类及cagrilintide既往安全性数据一致。
研究设计与样本
- REIMAGINE 1为随机、双盲、平行组、3a期研究,在6个国家42个中心开展。
- 主要终点为全分析集HbA1c自基线至第40周的变化;体重变化为预设次要终点。
临床怎么用
- 对于饮食运动控制不佳的早期2型糖尿病患者,每周一次cagrilintide-semaglutide可显著改善血糖并降低体重。
- 应用时需关注胃肠道不良反应,其安全性特征与GLP-1受体激动剂类一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of cagrilintide-semaglutide for people with type 2 diabetes inadequately controlled with diet and exercise. METHODS: REIMAGINE 1 was a randomised, double-blind, parallel-group, phase 3a study carried out at 42 sites (study sites included university hospitals, health-care centres, research centres, and other centres) in six countries. Adults aged 18 years or older with type 2 diabetes inadequately controlled with diet and exercise were randomly assigned (2:1:2:1) to receive once-weekly subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (cagrilintide-semaglutide [2·4 mg each]), placebo 2·4 mg plus 2·4 mg, cagrilintide 1·0 mg plus semaglutide 1·0 mg (cagrilintide-semaglutide [1·0 mg each]), or placebo 1·0 mg plus 1·0 mg for 40 weeks. Randomisation was done using a web-based system with a block size of six and stratified according to HbA1c less than 8·5% at screening and participation in the MRI substudy. Participants, care providers, investigators, and outcome assessors were masked within dose level and all participants received visually identical injections to maintain masking throughout the study. The primary endpoint was change in HbA1c from baseline to week 40 in the full analysis set; safety was assessed in all participants who received at least one dose of the trial product. Change in bodyweight from baseline to week 40 was a prespecified secondary endpoint. This study is registered with ClinicalTrials.gov, NCT06323174, and is complete. FINDINGS: Between March 19 and Dec 5, 2024, 294 people were screened for eligibility, 189 of whom were enrolled and randomly assigned to cagrilintide-semaglutide (2·4 mg each; n=62), cagrilintide-semaglutide (1·0 mg each; n=63), or placebo (n=64). 103 (54%) of 189 were male, 86 (46%) were female, 147 (78%) were White, and 26 (14%) were Asian. Baseline mean HbA1c was 7·8% (SD 0·7) and BMI was 35·2 kg/m2 (7·4). Using the efficacy estimand, the estimated mean change in HbA1c after 40 weeks was -1·8 percentage points (SE 0·1) with cagrilintide-semaglutide (2·4 mg each), -1·5 percentage points (0·1) with cagrilintide-semaglutide (1·0 mg each), and -0·1 percentage points (0·2) with placebo. This corresponded to an estimated treatment difference of -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001) for cagrilintide-semaglutide (2·4 mg each) versus placebo and -1·3 percentage points (-1·8 to -0·9; p<0·0001) for cagrilintide-semaglutide (1·0 mg each) versus placebo. Cagrilintide-semaglutide was superior to placebo with respect to estimated mean relative change in bodyweight from baseline to week 40 for cagrilintide-semaglutide (2·4 mg each; -13·8% [SE 1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -12·4 percentage points [95% CI -14·7 to -10·1]; p<0·0001) and cagrilintide-semaglutide (1·0 mg each; -11·8% [1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -10·4 percentage points [-12·9 to -8·0]; p<0·0001). Adverse events were reported by 49 (79%) of 62 participants in the cagrilintide-semaglutide (2·4 mg each) group, 47 (75%) of 63 in the cagrilintide-semaglutide (1·0 mg each) group, and 42 (66%) of 64 in the placebo group. Most adverse events were mild or moderate and gastrointestinal related. INTERPRETATION: In a population of people with early-stage type 2 diabetes inadequately controlled with diet and exercise, cagrilintide-semaglutide (2·4 mg each and 1·0 mg each) was superior to placebo in reducing HbA1c. The safety profile was consistent with the GLP-1 receptor agonist class and previous safety data for cagrilintide. These findings support cagrilintide-semaglutide as a potential novel and effective therapeutic intervention for people with early-stage type 2 diabetes. FUNDING: Novo Nordisk.
引用
- Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes Endocrinol. 2026. PMID: 42251860. doi:10.1016/S2213-8587(26)00126-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。